Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02447848 · ClinicalTrials.gov registry record · Phase 3

Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

A Phase 3 study, sponsored by Talphera.

Completed
Registry status
Phase 3
Development phase
76
Enrollment target

NCT02447848: Completed Phase 3 study, sponsored by Talphera.

NCT02447848 is a Phase 3 study that has completed, run by Talphera. The registered enrollment target is 76 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02447848, a Phase 3 study, has completed, sponsored by Talphera.

COMPLETED
Registry status
Phase 3
Development phase
76 participants
Enrollment target

Study Summary

To evaluate the safety and efficacy of sufentanil tablet (ST) 30 mcg in the management of moderate-to-severe acute pain in patients in an emergency room (ER) setting.

Primary Outcome

The primary efficacy endpoint is the time-weighted SPID1 evaluated from the patient questionnaire data. Pain intensity (PI) will be measured using an 11-point numerical rating scale (NRS) with 0 (no pain) and 10 (worst possible pain). The patient's rating of PI will be measured at baseline and at 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1, 2, 3, 4, and 5 hours following the first dose of study drug. The PID at each evaluation time point after the initiation of the first dose is the differen

Interventions

  • DRUG sufentanil sublingual 30 mcg tablet

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2015-10
Est. Completion 2016-07
Phase Phase 3
Talphera

18 total trials

What the finished NCT02447848 record still lists

NCT02447848 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 1 intervention - of which sufentanil sublingual 30 mcg tablet is the first listed.

NCT02447848 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02447848 about?

NCT02447848 is a clinical study titled "Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain". To evaluate the safety and efficacy of sufentanil tablet (ST) 30 mcg in the management of moderate-to-severe acute pain in patients in an emergency room (ER) setting.

What is the current status of trial NCT02447848?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 76 participants. The study started on 2015-10. Estimated completion is 2016-07.

What interventions are being tested in trial NCT02447848?

The interventions under investigation include: sufentanil sublingual 30 mcg tablet (DRUG).

Who is sponsoring clinical trial NCT02447848?

This trial is sponsored by Talphera, which has 18 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02447848's enrollment target sits among peer trials

76 1773rd of 2000 higher than 228 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02615184 · 76 participants · Phase 2

    A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

  • NCT02821741 · 76 participants · NA

    Effects of External Ear Stimulation on Pain Perception and Mood

  • NCT03019757 · 76 participants

    Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

  • NCT03353584 · 76 participants · NA

    Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02447848, the US trial registry maintained by the National Library of Medicine. NCT02447848 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.